Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 British Society for Rheumatology Annual Conference...
April 29 2019 - 8:25AM
Centrexion Therapeutics Corporation, a company focused on
developing non-opioid, non-addictive therapeutics for the treatment
of chronic pain, today announced it will present one poster on
CNTX-4975 at the 2019 British Society for Rheumatology (BSR) Annual
Conference taking place April 30-May 2, 2019 in Birmingham, UK and
four posters on CNTX-4975 at the Osteoarthritis Research Society
International (OARSI) 2019 World Congress taking place May 2-5,
2019 in Ontario, Canada.
“We have continued to make significant advances in refining our
proprietary cooling procedure technique for intra-articular
injection of CNTX-4975 for painful knee osteoarthritis, and are
pleased to report in these posters a nearly 50% reduction in
procedure time. We have demonstrated the maintenance of the lowered
joint temperature for 30 minutes after removal of the cooling wrap.
Importantly, even with the shortened procedure time, patient
comfort is maintained,” said Dr. Randall Stevens, chief medical
officer of Centrexion. “Our initial procedure technique was
conservative and designed with an emphasis on ensuring the blinding
of our clinical trials. We continue to conduct additional studies
to optimize the cooling procedure to meet the needs of patients and
clinicians in medical practice settings and look forward to
reporting additional new data at EULAR in
June.”
Full abstracts have been published in Rheumatology and are
available online at https://academic.oup.com/rheumatology. Details
of the poster presentation are listed below.
Title: Evaluation of Intra-articular CNTX-4975
(Highly Purified, Synthetic trans-Capsaicin) for Knee
Osteoarthritis (OA) Pain in Subjects With Radiographic Presence of
OA in the Opposite KneeSession Title: Wednesday
Poster ViewingPoster Number:
161Presentation Time: Wednesday, May 1, 9:00AM –
5:00PMLocation: The ICC, Birmingham - Halls 3 and
4
Full abstracts have been published in Osteoarthritis &
Cartilage and are available online at https://www.oarsijournal.com.
Details of the poster presentations are listed below.
Title: Effects of Skin Cooling on
Intra-articular Knee Temperature in Health SubjectsSession
Title: Poster Session 1 and 2Poster
Number: 708Presentation Time: Friday, May
3, 4:15PM – 5PM and Saturday, May 4, 4:15PM –
5:00PMLocation: Sheraton Centre Toronto - Sheraton
Hall / Osgoode & Foyers
Title: Intra-articular CNTX-4975 for
Osteoarthritis Knee Pain: Subgroup and Post Hoc Analyses of a
Randomized Phase 2 StudySession Title: Poster
Session 1 and 2Poster Number:
722Presentation Time: Friday, May 3, 4:15PM – 5PM
and Saturday, May 4, 4:15PM – 5:00PMLocation:
Sheraton Centre Toronto - Sheraton Hall / Osgoode & Foyers
Title: Procedure Pain Associated With
Intra-articular Injection of CNTX-4975 for Management of Painful
Osteoarthritis of the Knee Varies With Cooling Session
Title: Poster Session 1 and 2Poster
Number: 733Presentation Time: Friday, May
3, 4:15PM – 5PM and Saturday, May 4, 4:15PM –
5:00PMLocation: Sheraton Centre Toronto - Sheraton
Hall / Osgoode & Foyers
Title: Bilateral Intra-articular Injection of
CNTX-4975 for Management of Painful Osteoarthritis of the Knee:
Results at 6 Weeks From an Open-label TrialSession
Title: Poster Session 1 and 2Poster
Number: 734Presentation Time: Friday, May
3, 4:15PM – 5PM and Saturday, May 4, 4:15PM –
5:00PMLocation: Sheraton Centre Toronto - Sheraton
Hall / Osgoode & Foyers
About Osteoarthritis Osteoarthritis (“OA”) is
the most common joint disease in the United States, currently
affecting more than 30 million Americans, according to the U.S.
Centers for Disease Control. OA occurs when cartilage, the tissue
that envelops the structural bones within a joint, gradually
deteriorates. These changes cause pain, swelling and problems
moving the joint. Although OA can affect any joint, it most often
affects joints in the knees, hips, lower back and neck, small
joints of the fingers and the bases of the thumb and big toe. Over
time, patients with knee OA tend to become inactive due to pain and
joint stiffness and reduced function.
About CNTX-4975 CNTX-4975, Centrexion’s most
advanced product candidate, is an investigational synthetic,
ultra-pure intra-articular injection of trans-capsaicin for the
treatment of moderate to severe pain associated with knee OA.
CNTX-4975 is designed to be administered directly into the joint
where the pain stimulus originates and to selectively and locally
target and disrupt the signaling of pain-sensing nerve fibers. In
January 2018, CNTX-4975 was granted Fast Track Designation by the
U.S. Food and Drug Administration for the treatment of pain
associated with knee OA.
About Centrexion TherapeuticsCentrexion is a
late clinical-stage biopharmaceutical company focused on becoming
the leader in identifying, developing and commercializing novel,
non-opioid and non-addictive therapies to address the large unmet
medical need for the treatment of chronic pain. Centrexion’s
website address is http://www.centrexion.com.
Deshpande, B., et al. Number of Persons With Symptomatic Knee
Osteoarthritis in the US: Impact of Race and Ethnicity, Age, Sex,
and Obesity. Arthritis Care & Research. Published online
November 3, 2016
Media Contact Julie Normart, W2O pure +1 (559)
974-3245 jnormart@w2ogroup.com
Investor Contact Courtney Dugan, W2O pure +1
(212) 257-6723 cdugan@w2ogroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Jul 2023 to Jul 2024